Indepentednt logo

Did the intensive arm of the ACCORD trial aim too low?

Dr Alan BeggDr Alan Begg discusses the target levels of HbA1c in patients with diabetes in light of the latest study results

Chair of the SIGN Stable Angina Guideline Development Group and Member of the SIGN CHD Steering Group

Published online: 01 May 2008

Log in or register now for FREE in order to:

  • benefit from unlimited access to all pages, including:
    • 180+ guideline summaries
    • 1000+ evidence-based articles
  • review and leave comments on all articles and summaries
  • automatically track your reading and learning via your CPD tracker
  • on-demand webinars presented by leading clinical experts

Registration only takes 2 minutes and it will give you FREE access to all content across:



Need help? Email us